Galectin-1: A jack-of-all-trades in the resolution of acute and chronic inflammation

Journal of Immunology

Volumn 199, Issue 11, 2017, Pages 3721-3730

  Sundblad, Victoria ^a   Morosi, Luciano G ^a,b   Geffner, Jorge R ^b   Rabinovich, Gabriel A ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 1; GLYCAN;

ALLERGY; ASTHMA; AUTOIMMUNE DIABETES; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATION; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTION RESISTANCE; INFLAMMATORY BOWEL DISEASE; MOLECULAR BIOLOGY; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RESOLUTION ASSOCIATED MOLECULAR PATTERN; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; ACUTE DISEASE; ANIMAL; CELL MOTION; CHRONIC DISEASE; FEMALE; HYPERSENSITIVITY; IMMUNOLOGY; IMMUNOMODULATION; INFECTION; INFLAMMATION; MOLECULARLY TARGETED THERAPY; NEOPLASM;

ACUTE DISEASE; ANIMALS; AUTOIMMUNE DISEASES; CELL MOVEMENT; CHRONIC DISEASE; FEMALE; GALECTIN 1; HUMANS; HYPERSENSITIVITY; IMMUNOMODULATION; INFECTION; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; PREGNANCY;

EID: 85034742647     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1701172     Document Type: Review

References (142)

1. Buckley, C. D., D. W. Gilroy, C. N. Serhan, B. Stockinger, and P. P. Tak. 2013. The resolution of inflammation. Nat. Rev. Immunol. 13: 59–66.
2. Serhan, C. N. 2014. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510: 92–101.
3. Shields, A. M., G. S. Panayi, and V. M. Corrigall. 2011. Resolution-associated molecular patterns (RAMP): RAMParts defending immunological homeostasis? Clin. Exp. Immunol. 165: 292–300.
4. Méndez-Huergo, S. P., A. G. Blidner, and G. A. Rabinovich. 2017. Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis. Curr. Opin. Immunol. 45: 8–15.
5. Sato, S., C. St-Pierre, P. Bhaumik, and J. Nieminen. 2009. Galectins in innate immunity: dual functions of host soluble beta-galactoside-binding lectins as damage-associated molecular patterns (DAMPs) and as receptors for pathogen-associated molecular patterns (PAMPs). Immunol. Rev. 230: 172–187.
6. Cerliani, J. P., A. G. Blidner, M. A. Toscano, D. O. Croci, and G. A. Rabinovich. 2017. Translating the ‘sugar code’ into immune and vascular signaling programs. Trends Biochem. Sci. 42: 255–273.
7. Liu, F. T., R. J. Patterson, and J. L. Wang. 2002. Intracellular functions of galectins. Biochim. Biophys. Acta 1572: 263–273.
8. Rabinovich, G. A., M. A. Toscano, S. S. Jackson, and G. R. Vasta. 2007. Functions of cell surface galectin-glycoprotein lattices. Curr. Opin. Struct. Biol. 17: 513–520.
9. Nickel, W. 2003. The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. Eur. J. Biochem. 270: 2109–2119.
10. Cho, M., and R. D. Cummings. 1995. Galectin-1, a beta-galactoside-binding lectin in Chinese hamster ovary cells. II. Localization and biosynthesis. J. Biol. Chem. 270: 5207–5212.
11. Thiemann, S., and L. G. Baum. 2016. Galectins and immune responses-Just how do they do those things they do? Annu. Rev. Immunol. 34: 243–264.
12. Hsu, D. K., R. Y. Yang, Z. Pan, L. Yu, D. R. Salomon, W. P. Fung-Leung, and F. T. Liu. 2000. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am. J. Pathol. 156: 1073–1083.
13. Steichen, A. L., T. J. Simonson, S. L. Salmon, D. W. Metzger, B. B. Mishra, and J. Sharma. 2015. Alarmin function of galectin-9 in murine respiratory tularemia. PLoS One 10: e0123573.
14. Yip, P. K., A. Carrillo-Jimenez, P. King, A. Vilalta, K. Nomura, C. C. Chau, A. M. Egerton, Z. H. Liu, A. J. Shetty, J. L. Tremoleda, et al. 2017. Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration. Sci. Rep. 7: 41689.
15. Kouo, T., L. Huang, A. B. Pucsek, M. Cao, S. Solt, T. Armstrong, and E. Jaffee. 2015. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol. Res. 3: 412–423.
16. Daley, D., V. R. Mani, N. Mohan, N. Akkad, A. Ochi, D. W. Heindel, K. B. Lee, C. P. Zambirinis, G. S. B. Pandian, S. Savadkar, et al. 2017. Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nat. Med. 23: 556–567.
17. Di Lella, S., V. Sundblad, J. P. Cerliani, C. M. Guardia, D. A. Estrin, G. R. Vasta, and G. A. Rabinovich. 2011. When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry 50: 7842–7857.
18. Stowell, S. R., M. Cho, C. L. Feasley, C. M. Arthur, X. Song, J. K. Colucci, S. Karmakar, P. Mehta, M. Dias-Baruffi, R. P. McEver, and R. D. Cummings. 2009. Ligand reduces galectin-1 sensitivity to oxidative inactivation by enhancing dimer formation. J. Biol. Chem. 284: 4989–4999.
19. Croci, D. O., J. P. Cerliani, T. Dalotto-Moreno, S. P. Méndez-Huergo, I. D. Mascanfroni, S. Dergan-Dylon, M. A. Toscano, J. J. Caramelo, J. J. García-Vallejo, J. Ouyang, et al. 2014. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156: 744–758.
20. de la Fuente, H., A. Cruz-Adalia, G. Martinez Del Hoyo, D. Cibrián-Vera, P. Bonay, D. Pérez-Hernández, J. Vázquez, P. Navarro, R. Gutierrez-Gallego, M. Ramirez-Huesca, et al. 2014. The leukocyte activation receptor CD69 controls T cell differentiation through its interaction with galectin-1. Mol. Cell. Biol. 34: 2479–2487.
21. Bonzi, J., O. Bornet, S. Betzi, B. T. Kasper, L. K. Mahal, S. J. Mancini, C. Schiff, C. Sebban-Kreuzer, F. Guerlesquin, and L. Elantak. 2015. Pre-B cell receptor binding to galectin-1 modifies galectin-1/carbohydrate affinity to modulate specific galectin-1/glycan lattice interactions. Nat. Commun. 6: 6194.
22. Fuertes, M. B., L. L. Molinero, M. A. Toscano, J. M. Ilarregui, N. Rubinstein, L. Fainboim, N. W. Zwirner, and G. A. Rabinovich. 2004. Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase. Mol. Cell. Biochem. 267: 177–185.
23. Zuñiga, E., G. A. Rabinovich, M. M. Iglesias, and A. Gruppi. 2001. Regulated expression of galectin-1 during B-cell activation and implications for T-cell apoptosis. J. Leukoc. Biol. 70: 73–79.
24. Rabinovich, G., L. Castagna, C. Landa, C. M. Riera, and C. Sotomayor. 1996. Regulated expression of a 16-kd galectin-like protein in activated rat macrophages. J. Leukoc. Biol. 59: 363–370.
25. Garín, M. I., C. C. Chu, D. Golshayan, E. Cernuda-Morollón, R. Wait, and R. I. Lechler. 2007. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 109: 2058–2065.
26. Dalotto-Moreno, T., D. O. Croci, J. P. Cerliani, V. C. Martinez-Allo, S. Dergan-Dylon, S. P. Méndez-Huergo, J. C. Stupirski, D. Mazal, E. Osinaga, M. A. Toscano, et al. 2013. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res. 73: 1107–1117.
27. Ilarregui, J. M., D. O. Croci, G. A. Bianco, M. A. Toscano, M. Salatino, M. E. Vermeulen, J. R. Geffner, and G. A. Rabinovich. 2009. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 10: 981–991.
28. Tesone, A. J., M. R. Rutkowski, E. Brencicova, N. Svoronos, A. Perales-Puchalt, T. L. Stephen, M. J. Allegrezza, K. K. Payne, J. M. Nguyen, J. Wickramasinghe, et al. 2016. Satb1 overexpression drives tumor-promoting activities in cancer-associated dendritic cells. Cell Reports 14: 1774–1786.
29. Rutkowski, M. R., T. L. Stephen, N. Svoronos, M. J. Allegrezza, A. J. Tesone, A. Perales-Puchalt, E. Brencicova, X. Escovar-Fadul, J. M. Nguyen, M. G. Cadungog, et al. 2015. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27: 27–40.
30. Starossom, S. C., I. D. Mascanfroni, J. Imitola, L. Cao, K. Raddassi, S. F. Hernandez, R. Bassil, D. O. Croci, J. P. Cerliani, D. Delacour, et al. 2012. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 37: 249–263.
31. Blois, S. M., J. M. Ilarregui, M. Tometten, M. Garcia, A. S. Orsal, R. Cordo-Russo, M. A. Toscano, G. A. Bianco, P. Kobelt, B. Handjiski, et al. 2007. A pivotal role for galectin-1 in fetomaternal tolerance. Nat. Med. 13: 1450–1457.
32. Ramhorst, R. E., L. Giribaldi, L. Fraccaroli, M. A. Toscano, J. C. Stupirski, M. D. Romero, E. S. Durand, N. Rubinstein, A. Blaschitz, P. Sedlmayr, et al. 2012. Galectin-1 confers immune privilege to human trophoblast: implications in recurrent fetal loss. Glycobiology 22: 1374–1386.
33. Dettin, L., N. Rubinstein, A. Aoki, G. A. Rabinovich, and C. A. Maldonado. 2003. Regulated expression and ultrastructural localization of galectin-1, a pro-apoptotic beta-galactoside-binding lectin, during spermatogenesis in rat testis. Biol. Reprod. 68: 51–59.
34. Pérez, C. V., L. G. Gómez, G. S. Gualdoni, L. Lustig, G. A. Rabinovich, and V. A. Guazzone. 2015. Dual roles of endogenous and exogenous galectin-1 in the control of testicular immunopathology. Sci. Rep. 5: 12259.
35. Ridano, M. E., P. V. Subirada, M. C. Paz, V. E. Lorenc, J. C. Stupirski, A. L. Gramajo, J. D. Luna, D. O. Croci, G. A. Rabinovich, and M. C. Sánchez. 2017. Galectin-1 expression imprints a neurovascular phenotype in proliferative retinopathies and delineates responses to anti-VEGF. Oncotarget 8: 32505–32522
36. Suryawanshi, A., Z. Cao, T. Thitiprasert, T. S. Zaidi, and N. Panjwani. 2013. Galectin-1–mediated suppression of Pseudomonas aeruginosa–induced corneal immunopathology. J. Immunol. 190: 6397–6409.
37. Poncini, C. V., J. M. Ilarregui, E. I. Batalla, S. Engels, J. P. Cerliani, M. A. Cucher, Y. van Kooyk, S. M. González-Cappa, and G. A. Rabinovich. 2015. Trypanosoma cruzi infection imparts a regulatory program in dendritic cells and T cells via galectin-1–dependent mechanisms. J. Immunol. 195: 3311–3324.
38. Davicino, R. C., S. P. Méndez-Huergo, R. J. Eliçabe, J. C. Stupirski, I. Autenrieth, M. S. Di Genaro, and G. A. Rabinovich. 2017. Galectin-1–driven tolerogenic programs aggravate Yersinia enterocolitica infection by repressing antibacterial immunity. J. Immunol. 199: 1382–1392.
39. Santucci, L., S. Fiorucci, N. Rubinstein, A. Mencarelli, B. Palazzetti, B. Federici, G. A. Rabinovich, and A. Morelli. 2003. Galectin-1 suppresses experimental colitis in mice. Gastroenterology 124: 1381–1394.
40. Ge, X. N., S. G. Ha, Y. G. Greenberg, A. Rao, I. Bastan, A. G. Blidner, S. P. Rao, G. A. Rabinovich, and P. Sriramarao. 2016. Regulation of eosinophilia and allergic airway inflammation by the glycan-binding protein galectin-1. Proc. Natl. Acad. Sci. USA 113: E4837–E4846.
41. Xie, R. D., L. Z. Xu, L. T. Yang, S. Wang, Q. Liu, Z. G. Liu, and P. C. Yang. 2017. Galectin-1 inhibits oral-intestinal allergy syndrome. Oncotarget 8: 13214–13222.
42. Rubinstein, N., M. Alvarez, N. W. Zwirner, M. A. Toscano, J. M. Ilarregui, A. Bravo, J. Mordoh, L. Fainboim, O. L. Podhajcer, and G. A. Rabinovich. 2004. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5: 241–251.
43. Croci, D. O., M. Salatino, N. Rubinstein, J. P. Cerliani, L. E. Cavallin, H. J. Leung, J. Ouyang, J. M. Ilarregui, M. A. Toscano, C. I. Domaica, et al. 2012. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma. J. Exp. Med. 209: 1985–2000.
44. Martínez-Bosch, N., M. G. Fernández-Barrena, M. Moreno, E. Ortiz-Zapater, J. Munné-Collado, M. Iglesias, S. André, H. J. Gabius, R. F. Hwang, F. Poirier, et al. 2014. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res. 74: 3512–3524.
45. Bastón, J. I., R. I. Barañao, A. G. Ricci, M. A. Bilotas, C. N. Olivares, J. J. Singla, A. M. Gonzalez, J. C. Stupirski, D. O. Croci, G. A. Rabinovich, and G. F. Meresman. 2014. Targeting galectin-1–induced angiogenesis mitigates the severity of endometriosis. J. Pathol. 234: 329–337.
46. Blois, S. M., B. Y. Gueuvoghlanian-Silva, I. Tirado-González, M. R. Torloni, N. Freitag, R. Mattar, M. L. Conrad, L. Unverdorben, G. Barrientos, J. Knabl, et al. 2014. Getting too sweet: galectin-1 dysregulation in gestational diabetes mellitus. Mol. Hum. Reprod. 20: 644–649.
47. Seropian, I. M., J. P. Cerliani, S. Toldo, B. W. Van Tassell, J. M. Ilarregui, G. E. González, M. Matoso, F. N. Salloum, R. Melchior, R. J. Gelpi, et al. 2013. Galectin-1 controls cardiac inflammation and ventricular remodeling during acute myocardial infarction. Am. J. Pathol. 182: 29–40.
48. Medzhitov, R. 2008. Origin and physiological roles of inflammation. Nature 454: 428–435.
49. Nathan, C., and A. Ding. 2010. Nonresolving inflammation. Cell 140: 871–882.
50. Rabinovich, G. A., C. E. Sotomayor, C. M. Riera, I. Bianco, and S. G. Correa. 2000. Evidence of a role for galectin-1 in acute inflammation. Eur. J. Immunol. 30: 1331–1339.
51. La, M., T. V. Cao, G. Cerchiaro, K. Chilton, J. Hirabayashi, K. Kasai, S. M. Oliani, Y. Chernajovsky, and M. Perretti. 2003. A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation. Am. J. Pathol. 163: 1505–1515.
52. Cooper, D., L. V. Norling, and M. Perretti. 2008. Novel insights into the inhibitory effects of galectin-1 on neutrophil recruitment under flow. J. Leukoc. Biol. 83: 1459–1466.
53. Iqbal, A. J., A. L. Sampaio, F. Maione, K. V. Greco, T. Niki, M. Hirashima, M. Perretti, and D. Cooper. 2011. Endogenous galectin-1 and acute inflammation: emerging notion of a galectin-9 pro-resolving effect. Am. J. Pathol. 178: 1201–1209.
54. Stowell, S. R., S. Karmakar, C. M. Arthur, T. Ju, L. C. Rodrigues, T. B. Riul, M. Dias-Baruffi, J. Miner, R. P. McEver, and R. D. Cummings. 2009. Galectin-1 induces reversible phosphatidylserine exposure at the plasma membrane. Mol. Biol. Cell 20: 1408–1418.
55. Auvynet, C., S. Moreno, E. Melchy, I. Coronado-Martínez, J. L. Montiel, I. Aguilar-Delfin, and Y. Rosenstein. 2013. Galectin-1 promotes human neutrophil migration. Glycobiology 23: 32–42.
56. Correa, S. G., C. E. Sotomayor, M. P. Aoki, C. A. Maldonado, and G. A. Rabinovich. 2003. Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages. Glycobiology 13: 119–128.
57. Zúñiga, E., A. Gruppi, J. Hirabayashi, K. I. Kasai, and G. A. Rabinovich. 2001. Regulated expression and effect of galectin-1 on Trypanosoma cruzi–infected macrophages: modulation of microbicidal activity and survival. Infect. Immun. 69: 6804–6812.
58. Barrionuevo, P., M. Beigier-Bompadre, J. M. Ilarregui, M. A. Toscano, G. A. Bianco, M. A. Isturiz, and G. A. Rabinovich. 2007. A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J. Immunol. 178: 436–445.
59. Rostoker, R., H. Yaseen, S. Schif-Zuck, R. G. Lichtenstein, G. A. Rabinovich, and A. Ariel. 2013. Galectin-1 induces 12/15-lipoxygenase expression in murine macrophages and favors their conversion toward a pro-resolving phenotype. Prostaglandins Other Lipid Mediat. 107: 85–94.
60. Malik, R. K., R. R. Ghurye, D. J. Lawrence-Watt, and H. J. Stewart. 2009. Galectin-1 stimulates monocyte chemotaxis via the p44/42 MAP kinase pathway and a pertussis toxin-sensitive pathway. Glycobiology 19: 1402–1407.
61. Fulcher, J. A., S. T. Hashimi, E. L. Levroney, M. Pang, K. B. Gurney, L. G. Baum, and B. Lee. 2006. Galectin-1–matured human monocyte-derived dendritic cells have enhanced migration through extracellular matrix. J. Immunol. 177: 216–226.
62. Fulcher, J. A., M. H. Chang, S. Wang, T. Almazan, S. T. Hashimi, A. U. Eriksson, X. Wen, M. Pang, L. G. Baum, R. R. Singh, and B. Lee. 2009. Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J. Biol. Chem. 284: 26860–26870.
63. Thiemann, S., J. H. Man, M. H. Chang, B. Lee, and L. G. Baum. 2015. Galectin-1 regulates tissue exit of specific dendritic cell populations. J. Biol. Chem. 290: 22662–22677.
64. Rabinovich, G. A., and J. M. Ilarregui. 2009. Conveying glycan information into T-cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments. Immunol. Rev. 230: 144–159.
65. Stillman, B. N., D. K. Hsu, M. Pang, C. F. Brewer, P. Johnson, F. T. Liu, and L. G. Baum. 2006. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J. Immunol. 176: 778–789.
66. Matarrese, P., A. Tinari, E. Mormone, G. A. Bianco, M. A. Toscano, B. Ascione, G. A. Rabinovich, and W. Malorni. 2005. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpo-larization, budding, and fission. J. Biol. Chem. 280: 6969–6985.
67. Deák, M., Á. Hornung, J. Novák, D. Demydenko, E. Szabó, Á. Czibula, R. Fajka-Boja, É. Kriston-Pál, É. Monostori, and L. Kovács. 2015. Novel role for galectin-1 in T-cells under physiological and pathological conditions. Immunobiology 220: 483–489.
68. Stowell, S. R., S. Karmakar, C. J. Stowell, M. Dias-Baruffi, R. P. McEver, and R. D. Cummings. 2007. Human galectin-1, -2, and -4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood 109: 219–227.
69. Banh, A., J. Zhang, H. Cao, D. M. Bouley, S. Kwok, C. Kong, A. J. Giaccia, A. C. Koong, and Q. T. Le. 2011. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 71: 4423–4431.
70. Toscano, M. A., G. A. Bianco, J. M. Ilarregui, D. O. Croci, J. Correale, J. D. Hernandez, N. W. Zwirner, F. Poirier, E. M. Riley, L. G. Baum, and G. A. Rabinovich. 2007. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8: 825–834.
71. Salatino, M., D. O. Croci, G. A. Bianco, J. M. Ilarregui, M. A. Toscano, and G. A. Rabinovich. 2008. Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer. Expert Opin. Biol. Ther. 8: 45–57.
72. Liu, S. D., T. Tomassian, K. W. Bruhn, J. F. Miller, F. Poirier, and M. C. Miceli. 2009. Galectin-1 tunes TCR binding and signal transduction to regulate CD8 burst size. J. Immunol. 182: 5283–5295.
73. van der Leij, J., A. van den Berg, T. Blokzijl, G. Harms, H. van Goor, P. Zwiers, R. van Weeghel, S. Poppema, and L. Visser. 2004. Dimeric galectin-1 induces IL-10 production in T-lymphocytes: an important tool in the regulation of the immune response. J. Pathol. 204: 511–518.
74. Stowell, S. R., Y. Qian, S. Karmakar, N. S. Koyama, M. Dias-Baruffi, H. Leffler, R. P. McEver, and R. D. Cummings. 2008. Differential roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion. J. Immunol. 180: 3091–3102.
75. Cedeno-Laurent, F., M. Opperman, S. R. Barthel, V. K. Kuchroo, and C. J. Dimitroff. 2012. Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J. Immunol. 188: 3127–3137.
76. Toscano, M. A., A. G. Commodaro, J. M. Ilarregui, G. A. Bianco, A. Liberman, H. M. Serra, J. Hirabayashi, L. V. Rizzo, and G. A. Rabinovich. 2006. Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J. Immunol. 176: 6323–6332.
77. Wang, J., Z. H. Lu, H. J. Gabius, C. Rohowsky-Kochan, R. W. Ledeen, and G. Wu. 2009. Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J. Immunol. 182: 4036–4045.
78. Gauthier, L., B. Rossi, F. Roux, E. Termine, and C. Schiff. 2002. Galectin-1 is a stromal cell ligand of the pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR triggering. Proc. Natl. Acad. Sci. USA 99: 13014–13019.
79. Espeli, M., S. J. Mancini, C. Breton, F. Poirier, and C. Schiff. 2009. Impaired B-cell development at the pre-BII-cell stage in galectin-1–deficient mice due to inefficient pre-BII/stromal cell interactions. Blood 113: 5878–5886.
80. Elantak, L., M. Espeli, A. Boned, O. Bornet, J. Bonzi, L. Gauthier, M. Feracci, P. Roche, F. Guerlesquin, and C. Schiff. 2012. Structural basis for galectin-1–dependent pre-B cell receptor (pre-BCR) activation. J. Biol. Chem. 287: 44703–44713.
81. Croci, D. O., P. E. Morande, S. Dergan-Dylon, M. Borge, M. A. Toscano, J. C. Stupirski, R. F. Bezares, J. S. Avalos, M. Narbaitz, R. Gamberale, et al. 2013. Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1. Leukemia 27: 1413–1416.
82. Tsai, C. M., H. Y. Wu, T. H. Su, C. W. Kuo, H. W. Huang, C. H. Chung, C. S. Chen, K. H. Khoo, Y. J. Chen, and K. I. Lin. 2014. Phosphoproteomic analyses reveal that galectin-1 augments the dynamics of B-cell receptor signaling. J. Proteomics 103: 241–253.
83. Tabrizi, S. J., H. Niiro, M. Masui, G. Yoshimoto, T. Iino, Y. Kikushige, T. Wakasaki, E. Baba, S. Shimoda, T. Miyamoto, et al. 2009. T cell leukemia/ lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins. J. Immunol. 182: 1490–1499.
84. Anginot, A., M. Espeli, L. Chasson, S. J. Mancini, and C. Schiff. 2013. Galectin 1 modulates plasma cell homeostasis and regulates the humoral immune response. J. Immunol. 190: 5526–5533.
85. Mendez-Huergo, S. P., S. M. Maller, M. F. Farez, K. Mariño, J. Correale, and G. A. Rabinovich. 2014. Integration of lectin-glycan recognition systems and immune cell networks in CNS inflammation. Cytokine Growth Factor Rev. 25: 247–255.
86. Offner, H., B. Celnik, T. S. Bringman, D. Casentini-Borocz, G. E. Nedwin, and A. A. Vandenbark. 1990. Recombinant human beta-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 28: 177–184.
87. Mari, E. R., J. Rasouli, B. Ciric, J. N. Moore, J. R. Conejo-Garcia, N. Rajasagi, G. X. Zhang, G. A. Rabinovich, and A. Rostami. 2016. Galectin-1 is essential for the induction of MOG35-55–based intravenous tolerance in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 46: 1783–1796.
88. Rinaldi, M., L. Thomas, P. Mathieu, P. Carabias, M. F. Troncoso, J. M. Pasquini, G. A. Rabinovich, and L. A. Pasquini. 2016. Galectin-1 circumvents lysolecithin-induced demyelination through the modulation of microglial polarization/ phagocytosis and oligodendroglial differentiation. Neurobiol. Dis. 96: 127–143.
89. Aalinkeel, R., C. S. Mangum, E. Abou-Jaoude, J. L. Reynolds, M. Liu, K. Sundquist, N. U. Parikh, L. D. Chaves, M. J. Mammen, S. A. Schwartz, and S. D. Mahajan. 2017. Galectin-1 reduces neuroinflammation via modulation of nitric oxide-arginase signaling in HIV-1–transfected microglia: a gold nano-particle–galectin-1 “Nanoplex” a possible neurotherapeutic? J. Neuroimmune Pharmacol. 12: 133–151.
90. Rabinovich, G. A., M. M. Iglesias, N. M. Modesti, L. F. Castagna, C. Wolfenstein-Todel, C. M. Riera, and C. E. Sotomayor. 1998. Activated rat macrophages produce a galectin-1–like protein that induces apoptosis of T cells: biochemical and functional characterization. J. Immunol. 160: 4831–4840.
91. Rabinovich, G. A., A. Ariel, R. Hershkoviz, J. Hirabayashi, K. I. Kasai, and O. Lider. 1999. Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology 97: 100–106.
92. Rabinovich, G. A., G. Daly, H. Dreja, H. Tailor, C. M. Riera, J. Hirabayashi, and Y. Chernajovsky. 1999. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J. Exp. Med. 190: 385–398.
93. Harjacek, M., S. Diaz-Cano, M. De Miguel, H. Wolfe, C. A. Maldonado, and G. A. Rabinovich. 2001. Expression of galectins-1 and -3 correlates with defective mononuclear cell apoptosis in patients with juvenile idiopathic arthritis. J. Rheu-matol. 28: 1914–1922.
94. Wang, C. R., A. L. Shiau, S. Y. Chen, Z. S. Cheng, Y. T. Li, C. H. Lee, Y. T. Yo, C. W. Lo, Y. S. Lin, H. Y. Juan, et al. 2010. Intra-articular lentivirus-mediated delivery of galectin-3 shRNA and galectin-1 gene ameliorates collagen-induced arthritis. Gene Ther. 17: 1225–1233.
95. Filer, A., M. Bik, G. N. Parsonage, J. Fitton, E. Trebilcock, K. Howlett, M. Cook, K. Raza, D. L. Simmons, A. M. Thomas, et al. 2009. Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways. Arthritis Rheum. 60: 1604–1614.
96. Iqbal, A. J., D. Cooper, A. Vugler, B. R. Gittens, A. Moore, and M. Perretti. 2013. Endogenous galectin-1 exerts tonic inhibition on experimental arthritis. J. Immunol. 191: 171–177.
97. Zanon, Cde. F., N. M. Sonehara, A. P. Girol, C. D. Gil, and S. M. Oliani. 2015. Protective effects of the galectin-1 protein on in vivo and in vitro models of ocular inflammation. Mol. Vis. 21: 1036–1050
98. Rajasagi, N. K., A. Suryawanshi, S. Sehrawat, P. B. Reddy, S. Mulik, M. Hirashima, and B. T. Rouse. 2012. Galectin-1 reduces the severity of herpes simplex virus-induced ocular immunopathological lesions. J. Immunol. 188: 4631–4643.
99. Maldonado, C. A., L. F. Castagna, G. A. Rabinovich, and C. A. Landa. 1999. Immunocytochemical study of the distribution of a 16-kDa galectin in the chicken retina. Invest. Ophthalmol. Vis. Sci. 40: 2971–2977
100. Ishida, K., N. Panjwani, Z. Cao, and J. W. Streilein. 2003. Participation of pigment epithelium in ocular immune privilege. 3. Epithelia cultured from iris, ciliary body, and retina suppress T-cell activation by partially non-overlapping mechanisms. Ocul. Immunol. Inflamm. 11: 91–105.
101. Romero, M. D., J. C. Muiño, G. A. Bianco, M. Ferrero, C. P. Juarez, J. D. Luna, and G. A. Rabinovich. 2006. Circulating anti-galectin-1 antibodies are associated with the severity of ocular disease in autoimmune and infectious uveitis. Invest. Ophthalmol. Vis. Sci. 47: 1550–1556.
102. Gao, J., X. Wang, Y. Wang, F. Han, W. Cai, B. Zhao, Y. Li, S. Han, X. Wu, and D. Hu. 2016. Murine Sertoli cells promote the development of tolerogenic dendritic cells: a pivotal role of galectin-1. Immunology 148: 253–265.
103. Perone, M. J., S. Bertera, W. J. Shufesky, S. J. Divito, A. Montecalvo, A. R. Mathers, A. T. Larregina, M. Pang, N. Seth, K. W. Wucherpfennig, et al. 2009. Suppression of autoimmune diabetes by soluble galectin-1. J. Immunol. 182: 2641–2653.
104. D’Alise, A. M., V. Auyeung, M. Feuerer, J. Nishio, J. Fontenot, C. Benoist, and D. Mathis. 2008. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc. Natl. Acad. Sci. USA 105: 19857–19862.
105. Schneider, A., M. Rieck, S. Sanda, C. Pihoker, C. Greenbaum, and J. H. Buckner. 2008. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 181: 7350–7355.
106. Wu, G., Z. H. Lu, H. J. Gabius, R. W. Ledeen, and D. Bleich. 2011. Ganglioside GM1 deficiency in effector T cells from NOD mice induces resistance to regulatory T-cell suppression. Diabetes 60: 2341–2349.
107. Motran, C. C., K. M. Molinder, S. D. Liu, F. Poirier, and M. C. Miceli. 2008. Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function. Eur. J. Immunol. 38: 3015–3027.
108. Neurath, M. F. 2014. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14: 329–342.
109. Nalle, S. C., and J. R. Turner. 2015. Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease. Mucosal Immunol. 8: 720–730.
110. Muller, S., T. Schaffer, B. Flogerzi, A. Fleetwood, R. Weimann, A. M. Schoepfer, and F. Seibold. 2006. Galectin-3 modulates T cell activity and is reduced in the inflamed intestinal epithelium in IBD. Inflamm. Bowel Dis. 12: 588–597.
111. Paclik, D., U. Berndt, C. Guzy, A. Dankof, S. Danese, P. Holzloehner, S. Rosewicz, B. Wiedenmann, B. M. Wittig, A. U. Dignass, and A. Sturm. 2008. Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice. J. Mol. Med. (Berl.) 86: 1395–1406.
112. Paclik, D., S. Danese, U. Berndt, B. Wiedenmann, A. Dignass, and A. Sturm. 2008. Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLoS One 3: e2629.
113. Nishida, A., K. Nagahama, H. Imaeda, A. Ogawa, C. W. Lau, T. Kobayashi, T. Hisamatsu, F. I. Preffer, E. Mizoguchi, H. Ikeuchi, et al. 2012. Inducible colitis-associated glycome capable of stimulating the proliferation of memory CD4+ T cells. J. Exp. Med. 209: 2383–2394.
114. Papa Gobbi, R., N. De Francesco, C. Bondar, C. Muglia, F. Chirdo, M. Rumbo, A. Rocca, M. A. Toscano, A. Sambuelli, G. A. Rabinovich, and G. H. Docena. 2016. A galectin-specific signature in the gut delineates Crohn’s disease and ulcerative colitis from other human inflammatory intestinal disorders. Biofactors 42: 93–105
115. Muglia, C., N. Mercer, M. A. Toscano, M. Schattner, R. Pozner, J. P. Cerliani, R. P. Gobbi, G. A. Rabinovich, and G. H. Docena. 2011. The glycan-binding protein galectin-1 controls survival of epithelial cells along the crypt-villus axis of small intestine. Cell Death Dis. 2: e163.
116. Muglia, C. I., R. P. Gobbi, P. Smaldini, M. L. Delgado, M. Candia, C. Zanuzzi, A. Sambuelli, A. Rocca, M. A. Toscano, G. A. Rabinovich, and G. H. Docena. 2016. Inflammation controls sensitivity of human and mouse intestinal epithelial cells to galectin-1. J. Cell. Physiol. 231: 1575–1585.
117. Robinson, D., M. Humbert, R. Buhl, A. A. Cruz, H. Inoue, S. Korom, N. A. Hanania, and P. Nair. 2017. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin. Exp. Allergy 47: 161–175.
118. Norling, L. V., A. L. Sampaio, D. Cooper, and M. Perretti. 2008. Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking. FASEB J. 22: 682–690.
119. Sanchez-Cuellar, S., H. de la Fuente, A. Cruz-Adalia, A. Lamana, D. Cibrian, R. M. Giron, A. Vara, F. Sanchez-Madrid, and J. Ancochea. 2012. Reduced expression of galectin-1 and galectin-9 by leucocytes in asthma patients. Clin. Exp. Immunol. 170: 365–374.
120. Delbrouck, C., I. Doyen, N. Belot, C. Decaestecker, R. Ghanooni, A. de Lavareille, H. Kaltner, G. Choufani, A. Danguy, G. Vandenhoven, et al. 2002. Galectin-1 is overexpressed in nasal polyps under budesonide and inhibits eosinophil migration. Lab. Invest. 82: 147–158.
121. Sena, A. A., P. J. Provazzi, A. M. Fernandes, P. M. Cury, P. Rahal, and S. M. Oliani. 2006. Spatial expression of two anti-inflammatory mediators, annexin 1 and galectin-1, in nasal polyposis. Clin. Exp. Allergy 36: 1260–1267.
122. Yang, L. T., Q. Shu, X. Q. Luo, Z. Q. Liu, S. Q. Qiu, J. Q. Liu, H. J. Guo, L. J. Li, M. G. Li, D. B. Liu, et al. 2017. Long-term effects: Galectin-1 and specific immunotherapy for allergic responses in the intestine. Allergy. DOI: 10.1111/all.13256.
123. Blidner, A. G., and G. A. Rabinovich. 2013. ‘Sweetening’ pregnancy: galectins at the fetomaternal interface. Am. J. Reprod. Immunol. 69: 369–382.
124. Tirado-González, I., N. Freitag, G. Barrientos, V. Shaikly, O. Nagaeva, M. Strand, L. Kjellberg, B. F. Klapp, L. Mincheva-Nilsson, M. Cohen, and S. M. Blois. 2013. Galectin-1 influences trophoblast immune evasion and emerges as a predictive factor for the outcome of pregnancy. Mol. Hum. Reprod. 19: 43–53.
125. Kopcow, H. D., F. Rosetti, Y. Leung, D. S. Allan, J. L. Kutok, and J. L. Strominger. 2008. T cell apoptosis at the maternal-fetal interface in early human pregnancy, involvement of galectin-1. Proc. Natl. Acad. Sci. USA 105: 18472–18477.
126. Gómez-Chávez, F., V. Castro-Leyva, A. Espejel-Núñez, R. G. Zamora-Mendoza, H. Rosas-Vargas, J. C. Cancino-Díaz, M. E. Cancino-Díaz, G. Estrada-Gutierrez, and S. Rodríguez-Martínez. 2015. Galectin-1 reduced the effect of LPS on the IL-6 production in decidual cells by inhibiting LPS on the stimulation of IkBz. J. Reprod. Immunol. 112: 46–52.
127. Woidacki, K., M. Popovic, M. Metz, A. Schumacher, N. Linzke, A. Teles, F. Poirier, S. Fest, F. Jensen, G. A. Rabinovich, et al. 2013. Mast cells rescue implantation defects caused by c-kit deficiency. Cell Death Dis. 4: e462.
128. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267–296.
129. Cedeno-Laurent, F., M. J. Opperman, S. R. Barthel, D. Hays, T. Schatton, Q. Zhan, X. He, K. L. Matta, J. G. Supko, M. H. Frank, et al. 2012. Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J. Invest. Dermatol. 132: 410–420.
130. Juszczynski, P., J. Ouyang, S. Monti, S. J. Rodig, K. Takeyama, J. Abramson, W. Chen, J. L. Kutok, G. A. Rabinovich, and M. A. Shipp. 2007. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA 104: 13134–13139.
131. Ouyang, J., P. Juszczynski, S. J. Rodig, M. R. Green, E. O’Donnell, T. Currie, M. Armant, K. Takeyama, S. Monti, G. A. Rabinovich, et al. 2011. Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood 117: 4315–4322.
132. Ito, K., and S. J. Ralph. 2012. Inhibiting galectin-1 reduces murine lung metastasis with increased CD4(+) and CD8(+) T cells and reduced cancer cell adherence. Clin. Exp. Metastasis 29: 561–572.
133. Verschuere, T., J. Toelen, W. Maes, F. Poirier, L. Boon, T. Tousseyn, T. Mathivet, H. Gerhardt, V. Mathieu, R. Kiss, et al. 2014. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Int. J. Cancer 134: 873–884.
134. Baker, G. J., P. Chockley, D. Zamler, M. G. Castro, and P. R. Lowenstein. 2016. Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells. OncoImmunology 5: e1163461.
135. Soldati, R., E. Berger, A. C. Zenclussen, G. Jorch, H. N. Lode, M. Salatino, G. A. Rabinovich, and S. Fest. 2012. Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int. J. Cancer 131: 1131–1141.
136. Cedeno-Laurent, F., R. Watanabe, J. E. Teague, T. S. Kupper, R. A. Clark, and C. J. Dimitroff. 2012. Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 119: 3534–3538.
137. Demotte, N., V. Stroobant, P. J. Courtoy, P. Van Der Smissen, D. Colau, I. F. Luescher, C. Hivroz, J. Nicaise, J. L. Squifflet, M. Mourad, et al. 2008. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 28: 414–424.
138. Wu, X., J. Li, E. M. Connolly, X. Liao, J. Ouyang, A. Giobbie-Hurder, D. Lawrence, D. McDermott, G. Murphy, J. Zhou, et al. 2017. Combined Anti-VEGF and Anti–CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes. Cancer Immunol. Res. 5: 446–454.
139. Lykken, J. M., M. Horikawa, V. Minard-Colin, M. Kamata, T. Miyagaki, J. C. Poe, and T. F. Tedder. 2016. Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. Blood 127: 1886–1895.
140. Fichorova, R. N., H. S. Yamamoto, T. Fashemi, E. Foley, S. Ryan, N. Beatty, H. Dawood, G. R. Hayes, G. St-Pierre, S. Sato, and B. N. Singh. 2016. Trichomonas vaginalis lipophosphoglycan exploits binding to galectin-1 and -3 to modulate epithelial immunity. J. Biol. Chem. 291: 998–1013.
141. Vasta, G. R., C. Feng, N. González-Montalbán, J. Mancini, L. Yang, K. Abernathy, G. Frost, and C. Palm. 2017. Functions of galectins as ‘self/non-self’-recognition and effector factors. Pathog. Dis. DOI: 10.1093/femspd/ftx046.
142. Cagnoni, A. J., J. M. Pérez Sáez, G. A. Rabinovich, and K. V. Mariño. 2016. Turning-off signaling by siglecs, selectins, and galectins: Chemical inhibition of glycan-dependent interactions in cancer. Front. Oncol. 6: 109.